You are here

Subcutaneous Velcade Gains FDA Nod

The Takeda Oncology Company said Monday that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for its Velcade (bortezomib) drug to include subcutaneous administration.

The FDA nod is for all approved indications of Velcade — multiple myeloma and mantle cell lymphoma after at least one prior therapy, the company said.

The approval was based on results from a randomized Phase 3 trial in 222 patients with relapsed multiple myeloma who had not previously taken Velcade. The primary goal of the trial was to show that single-agent subcutaneous Velcade retained at least 60 percent of the overall response rate after four cycles compared to single-agent intravenous drug administration. The secondary endpoints of the study included safety and tolerability, time to progression, progression-free survival and one-year overall survival.

Read the full article here.

Recent Headlines

New model uses piezoelectric material used in microphones and high-end speakers
Rozanolixizumab touted as possible alternative to standard therapy of corticosteroids, intravenous immunoglobulin
Company says it is offering a more affordable generic to the agent used to treat varicose veins
Company, FDA held a meeting to discuss trials in bunion, "tummy tuck" patients
Intrauterine environment may have a 'programming effect' on fetal heart
Heart rate variability may pinpoint who will benefit
Researchers found that ECMO before transplant tripled chance of a long hospital stay